` 4519 (Chugai Pharmaceutical Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4519
vs
Nikkei 225

Over the past 12 months, has significantly outperformed Nikkei 225, delivering a return of 53% compared to the Nikkei 225's 3% drop.

Stocks Performance
4519 vs Nikkei 225

Loading
4519
Nikkei 225
Add Stock
www.alphaspread.com

Performance Gap
4519 vs Nikkei 225

Loading
4519
Nikkei 225
Difference
www.alphaspread.com

Performance By Year
4519 vs Nikkei 225

Loading
4519
Nikkei 225
Add Stock

Competitors Performance
Chugai Pharmaceutical Co Ltd vs Peers

Nikkei 225
4519
LLY
JNJ
NOVO B
ROG
Add Stock

Chugai Pharmaceutical Co Ltd
Glance View

Economic Moat
Narrow
Market Cap
12.1T JPY
Industry
Pharmaceuticals

Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.

Intrinsic Value
4 328.73 JPY
Overvaluation 41%
Intrinsic Value
Price
Back to Top